Literature DB >> 3243736

Laboratory assessment of lomefloxacin (SC-47111) in comparison with norfloxacin.

R Edwards1, M Kanematsu, D Greenwood.   

Abstract

The activity of lomefloxacin and norfloxacin against 681 bacterial strains, including 520 strains isolated from infected urine was assessed in vitro. All strains were tested in two inocula and the susceptibility of urinary isolates was evaluated at three pH levels. Lomefloxacin displayed a broad spectrum of antibacterial activity which was similar to that of norfloxacin and which was independent of inoculum size. Good activity was shown for lomefloxacin against all Gram-negative urinary pathogens: strains of Pseudomonas spp and nalidixic acid-resistant enterobacteria were the least susceptible, indicating a degree of cross resistance between newer quinolones and nalidixic acid. Lomefloxacin generally showed more modest activity against Gram-positive cocci and bacteroides than against enterobacteria. Under the acidic conditions that commonly prevail in urine the activity of both compounds against Gram-negative urinary pathogens was markedly reduced, whereas strains of Gram-positive cocci were only minimally affected.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3243736     DOI: 10.1093/jac/22.6.885

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

Review 1.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

2.  Studies on the emergence of resistance to lomefloxacin in vitro.

Authors:  M Kanematsu; D Greenwood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

3.  Bactericidal activity of enoxacin and lomefloxacin against Escherichia coli KL16.

Authors:  C S Lewin; S G Amyes; J T Smith
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.